double Dragon

HGH 191AA (36iu vial) Dosage Protocol

HGH 191AA is recombinant human growth hormone (somatropin) identical to endogenous GH, studied extensively for its effects on body composition, metabolism, and tissue repair^[1]^[7]. Clinical protocols typically employ subcutaneous administration once daily to mimic physiological GH secretion patterns^[2]^[3]. This educational protocol presents a gradual titration approach using practical dilution for precise insulin-syringe measurements.

Reconstitute: Add 2.0 mL bacteriostatic water → ~18 IU/mL concentration (~18 mcg/mL).
Typical daily range: 150–500 mcg (conservative replacement protocols)^[1] to 1000–2000 mcg (advanced metabolic studies)^[4].
Easy measuring: At 18 IU/mL, 1 unit = 0.01 mL ≈ 0.18 IU on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Educational guide for reconstitution and weekly dosing

Standard / Gradual Titration ( 2 mL = ~18 IU/mL)

Week	Daily Dose (mcg)	Units (per injection) (mL)
Week 1	200 mcg	3.3 units
Week 2	300 mcg	5.0units
Week 3	400 mcg	6.7 units
Week 4	500 mcg	8.3 units
Week 5	600 mcg	10 units
Week 6	700 mcg	11.7 units
Week 7	800 mcg	13.3 units
Week 8	900 mcg	15 units

Frequency: Inject once daily subcutaneously, preferably at bedtime to mimic physiological GH secretion^[2]. Rotate injection sites to prevent lipoatrophy^[3]. This 8-week protocol represents a conservative approach with gradual dose escalation by approximately 100 mcg per week.

Reconstitution Steps

Draw 2.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Use within 4 weeks of reconstitution^[16].

Extended 12-Week Protocol (Optional)

Week	Daily Dose (mcg)	Units (per injection) (mL)
Week 9	1000 mcg	16.7 units
Week 10	1100 mcg	18.3 units
Week 11	1200 mcg	20 units
Week 12	1300 mcg	21.7 units

Note: The 12-week extension reaches higher daily doses (1000–1300 mcg) that have been explored in performance and metabolic research settings^[4]. These doses yield more significant physiological effects but also increase the potential for side effects. Further extension to 16 weeks (reaching 1700 mcg daily) may be considered in advanced protocols, though such aggressive regimens should be undertaken with appropriate monitoring.

Reconstitution Steps

Draw 2.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake vigorously to preserve protein structure)^[5].
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Plan based on an 8–16 week daily protocol with gradual titration.

Peptide Vials (HGH 191AA, 36 IU / 2 IU):
- 8 weeks ≈ 2 vials
- 12 weeks ≈ 3 vials
- 16 weeks ≈ 4 vials
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use ~2.0 mL per vial for reconstitution.
- 8 weeks (10 vials): 30 mL → 3 × 10 mL bottles
- 12 weeks (19 vials): 57 mL → 6 × 10 mL bottles
- 16 weeks (32 vials): 96 mL → 10 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes

Concise summary of the once-weekly regimen.

Goal: Support increases in lean body mass, reductions in adipose tissue, and enhanced metabolic function^[7]^[8].
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired for advanced protocols).
Dose Range: Conservative: 150–500 mcg daily^[1]; Advanced: 1000–2000 mcg daily^[4].
Reconstitution: 2.0 mL per 18 IU/ ml vial (~0.18 iu/mL) for accurate unit measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Suggested weekly titration approach from clinical trials.

Start: 200 mcg daily; increase by ~100 mcg each week as tolerated.
Conservative Target: 400–900 mcg daily by Weeks 4–8^[1]^[8].
Advanced Target: 1000–1300 mcg daily by Weeks 9–12 (performance/metabolic research protocols)^[4].
Frequency: Once per day (subcutaneous), preferably at bedtime^[2].
Cycle Length: 8–12 weeks standard; optional extension to 16 weeks with appropriate monitoring.
Timing: Evening or bedtime administration preferred; rotate injection sites systematically^[3].

Proper storage preserves peptide quality and stability.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); stable for several weeks when stored properly^[5].
Allow vials to reach room temperature before opening to reduce condensation uptake.
Critical: Avoid freeze–thaw cycles of reconstituted peptide, as freezing can denature the protein^[5].

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each injection; dispose in a sharps container.
Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and prevent lipoatrophy^[3].
Inject slowly; wait a few seconds before withdrawing the needle to minimize leakage.
Document daily dose, injection site, and any observed effects to maintain consistency and track tolerance.
HGH must be administered by injection; oral administration would be ineffective due to peptide degradation in the digestive system^[6].

HGH 191AA is recombinant human growth hormone (somatropin) that is structurally identical to endogenous GH secreted by the pituitary gland^[1]^[5]. Clinical studies demonstrate that GH administration promotes increases in lean body mass, reductions in adipose tissue, and improvements in body composition through multiple mechanisms including enhanced lipolysis, increased protein synthesis, and stimulation of IGF-1 production^[7]^[8]. Pivotal research by Rudman and colleagues showed that six months of HGH administration in older men significantly increased lean body mass and decreased adipose mass compared to placebo^[7]. Long-term follow-up studies in adults with GH deficiency have demonstrated sustained improvements in muscle strength and body composition with maintenance dosing^[8].

Subcutaneous administration once daily, particularly at bedtime, is designed to mimic physiological patterns of endogenous GH secretion^[2]^[3]. Dosing protocols vary based on therapeutic goals: conservative replacement protocols typically employ 150–500 mcg daily^[1], while advanced metabolic and performance research protocols may utilize 1000–2000 mcg daily^[4]. Higher doses produce more pronounced physiological effects but also carry increased risk of side effects including fluid retention, joint discomfort, and potential metabolic disturbances^[2].

Observations from clinical research literature.

Potential Benefits

Increases in lean body mass and reductions in adipose tissue in clinical studies^[7]^[8].
Enhanced fat oxidation and lipolysis in dose-dependent manner^[4].
Sustained improvements in muscle strength and body composition with long-term use in GH-deficient adults^[8].
Improved metabolic parameters in appropriate clinical contexts^[1]^[2].

Potential Side Effects

Injection site reactions (redness, irritation); can be minimized by proper rotation technique^[3].
Fluid retention and peripheral edema, particularly at higher doses^[2].
Joint discomfort or arthralgias reported in some clinical protocols.
Potential glucose metabolism effects; monitoring may be warranted in extended protocols^[2].
Risk of lipoatrophy at injection sites if rotation is inadequate^[3].

Note: While research in healthy athletes showed GH increased lean body mass, it did not significantly improve muscle strength or exercise performance in systematic reviews^[10]. Side effects and benefits are dose-dependent, with higher doses yielding more pronounced effects but also increased risk profiles.

Complementary strategies for optimal metabolic outcomes.

Maintain adequate protein intake (1.6–2.2 g/kg body weight) to support anabolic processes stimulated by GH.
Combine resistance training and progressive overload to maximize lean mass gains and strength improvements.
Include cardiovascular activity to enhance metabolic adaptations and fat oxidation.
Prioritize sleep quality and duration (7–9 hours) to support endogenous recovery processes.
Manage stress and cortisol levels, as chronic stress can interfere with GH signaling and metabolic outcomes.
Ensure adequate hydration, particularly at higher doses where fluid retention may occur.

Subcutaneous injection guidance from clinical best-practice resources^[11]^[12].

Clean the vial stopper and injection site with alcohol; allow to air dry completely.
Pinch a skinfold at the injection site; insert the needle at 45–90° into subcutaneous tissue^[11].
Do not aspirate for subcutaneous injections; inject slowly and steadily^[11].
Rotate sites systematically (abdomen, thighs, upper arms) to prevent lipohypertrophy and lipoatrophy^[3]^[13].
Common subcutaneous sites: abdomen (at least 2 inches from navel), outer thighs, upper arms (posterior surface)^[12].
Wait a few seconds after injection before withdrawing needle to minimize solution leakage.

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. HGH 191AA is a research peptide. Always consult qualified healthcare professionals before beginning any peptide protocol.

References

— Adult GH deficiency dosing: recommended start 0.45–0.90 IU (0.15–0.30 mg) SC daily; maintenance dose seldom exceeds 4 IU (≈1.33 mg) daily

— HIV-associated wasting dose: 0.1 mg/kg SC daily (up to ~6 mg/day); administer injections subcutaneously, preferably at bedtime

— Subcutaneous injection technique: site rotation to prevent lipoatrophy; recommends 0.15–0.30 mg per day to start in adults, titrating up to ~1.3 mg/day as needed

— GH usage and abuse review: moderate doses of GH (70–400 mcg in healthy adults) produce dose-dependent increases in lipolysis and fat oxidation

— Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760; protocol details, dosing regimens)

— Lyophilized 191aa HGH is a sterile, white powder for SC or IM injection after reconstitution with bacteriostatic water; potency: 5 mg ≈ 15 IU and 8.8 mg ≈ 26.4 IU

— HGH 191AA is provided as a lyophilized powder intended for subcutaneous (or intramuscular) injection after reconstitution with bacteriostatic water

— Pivotal study in older men: six months of HGH (0.03 mg/kg 3× weekly) significantly increased lean body mass and decreased adipose mass compared to placebo

— 10-year adult GH deficiency follow-up: initial ~0.72 mg/day GH replacement (then reduced to ~0.37 mg/day long-term) led to sustained increases in muscle strength and improved body composition

— Trial in 60–77 y/o adults: low-dose GH (~0.16 mg/day for 12 months) was administered to evaluate cognitive effects, illustrating a conservative dosing regimen

— Systematic review of GH in healthy athletes: GH administration increased lean body mass but did not significantly improve muscle strength or exercise performance

— Subcutaneous injection technique: angle/site selection; no aspiration required for subcutaneous route

— Technique diagram and site guidance for subcutaneous injections

— Best practices for injection: asepsis, preparation, and administration techniques

— HGH 191AA (36 IU / 18 IU/ml) product page with quality and batch documentation

Mechanism Breakdown — 3rd Party Analysis

This video provides an external overview on HGH

External Source

Titration schedule.

Standard research titration model. Adjust under qualified clinical observation only. Not for human therapeutic use.

Phase 01

Wk 1 — 4

1-2 IU

Once daily (Night)

Initiation · tolerance assessment

Phase 02

Wk 5 — 8

2-4 IU

Once daily (Night)

Standard titration step

Phase 03

Wk 9 — 12

4 IU

Once daily

Maintenance evaluation

Phase 04

Wk 13+

4-6 IU

Twice daily (Morning + Night)

Optional research extension

Research use only.

HGH is supplied strictly for in-vitro laboratory research and biochemical analysis. It is not intended for human consumption, diagnostic use, veterinary application or therapeutic administration of any kind.

Handling must be performed by qualified personnel in compliance with applicable institutional and jurisdictional safety standards. The information contained on this protocol sheet is provided for educational and reference purposes only and does not constitute medical advice.

Not for human use
Store at 2–8 °C, protected from light

Reconstitute under aseptic conditions
Document all research observations

Gold Tier Catalogue

Explore the full British Dragon research line.

Premium-tier compounds engineered for serious metabolic, longevity and performance research programs.

double Dragon

HGH 191AA (36iu vial) Dosage Protocol

HGH 191AA (36iu vial) Dosage Protocol

Table of Contents

Quickstart Highlights

Dosing & Reconstitution Guide

Standard / Gradual Titration ( 2 mL = ~18 IU/mL)

Reconstitution Steps

Extended 12-Week Protocol (Optional)

Reconstitution Steps

Supplies Needed

Protocol Overview

Dosing Protocol

Storage Instructions

Important Notes

How This Works

Potential Benefits & Side Effects

Potential Benefits

Potential Side Effects

Lifestyle Factors

Injection Technique

Video

Important Note

References

Mechanism Breakdown — 3rd Party Analysis

Titration schedule.

Phase 01

Wk 1 — 4

1-2 IU

Once daily (Night)

Initiation · tolerance assessment

Phase 02

Wk 5 — 8

2-4 IU

Once daily (Night)

Standard titration step

Phase 03

Wk 9 — 12

4 IU

Once daily

Maintenance evaluation

Phase 04

Wk 13+

4-6 IU

Twice daily (Morning + Night)

Optional research extension

Research use only.

Gold Tier Catalogue

Explore the full British Dragon research line.